ERBB2 and breast cancer: Consequently, the aim of this clinical feasibility trial was to assess whether 89Zr-trastuzumab PET supports clinical decision making in patients suspected of metastatic or locally recurrent HER2-positive breast cancer, presenting with a dilemma defined as failure of the standard work-up to evaluate the present HER2 status of their disease.